Project Details
Description
Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine (COVID-19 Vaccine Moderna®; Moderna) and COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria®, AstraZeneca)
Trial design: A prospective, post marketing, randomized, partially single blind, multicenter, interventional study
Trial design: A prospective, post marketing, randomized, partially single blind, multicenter, interventional study
| Acronym | IMCOVAS |
|---|---|
| Status | Finished |
| Effective start/end date | 21/05/21 → 31/03/23 |
Funding
- Belgian Health Care Knowledge Centre: €452,766.02
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.